Search Results
Showing 1 of 1 results
Why Teva is Investing Over One Billion Dollars in Biologics in Europe
With demand for biopharmaceutical products on the rise, Teva is investing in biologics production technologies for Active Pharmaceutical Ingredients (APIs) with cells for biosimilars and novel biologics. We meet Teva teams on the ground in the biologics manufacturing and supply operations site in Ulm to find out more.
